250 results about "Amniotic liquid" patented technology

The invention relates to a method for the early non-invasive diagnosis of fetal aneuploidy. In particular, the invention concerns the diagnosis of fetal aneuploidy by identifying protein expression patterns characteristics of fetal aneuploidy in a maternal biological fluid, such as maternal serum or amniotic fluid.

The invention provides an exosome separation method and a separation device thereof. The exosome separation method comprises the steps: firstly filtering or centrifuging blood, urea, saliva, cerebrospinal fluid, milk, ascetic fluid or amniotic fluid to remove impurities larger than 1 micrometer; then utilizing an even pore diameter anodized aluminum oxide film with the pore diameter correspondingto the diameter size of the exosome to filter, collecting filtrate or exosome on the even pore diameter anodized aluminum oxide film to obtain required exosome. The exosome separation device comprisesa membrane filter with the even pore diameter anodized aluminum oxide film as a filter membrane. By means of the separation method and the separation device thereof disclosed by the invention, the exosome can be simply and efficiently separated, the different sizes of exosome can be cut out and classified, and the different sizes of exosome can be respectively and correspondingly analyzed, researched and applied.

The invention discloses a probe and a kit for detecting pseudo-hypertrophic muscular dystrophy. The probe for detecting pseudo-hypertrophic muscular dystrophy comprises nucleic acid sequences shown by SEQ NO:1-SEQ ID NO:546, and the kit for detecting pseudo-hypertrophic muscular dystrophy comprises nucleic acid sequences shown by SEQ ID NO:1-SEQ ID NO:546. The probe and the kit for detecting pseudo-hypertrophic muscular dystrophy can be used for detecting complete mutation information of DMD genes, including exon deletion/repetition and point mutation, have the advantages of completeness, rapidness, accuracy and appropriate price, and can be used for solving the problems of DMD molecular diagnosis; the kit disclosed by the invention is suitable for detection of various tissue samples of muscle, blood, amniotic fluid and the like, can detect pathogenic mutation of exons and introns as well as known mutations and unreported pathogenic mutations, and is also used for detecting whether patient genotypes are corrected or not after stem cell therapy.

The invention relates to an amplification composition for detecting abnormal number of chromosomal aneuploid and a rapid detection kit, and belongs to the technical field of biology. The amplification composition can be used for amplification detection of STR sites related to 8 21# chromosomes, 6 18# chromosomes, 6 13# chromosomes and 3 X chromosomes and amplification detection of four amelo; all sites can be amplified by a quantitative fluorescent PCR (QF-PCR) technology, so as to detect the abnormal number of 21, 18, 13, X and Y chromosomal aneuploid. According to the kit, detection cycle is short, so the result can be obtained within 5 hours after obtaining the sample; the sensitivity is high; DNA at nanogram level, which is equal to DNA contained in 100 cells, is needed for each detection, so few samples are needed; 1 to 2ml of amniotic fluid can be collected to meet the demand; due to high sensitivity, a chimera containing more than 10% of trisomies can be detected.

The invention discloses four cell types which have wide heteroplastic transplantation application prospect and can be effectively induced into induced pluripotent stem (iPS) cells. The origins of three cell types are placental tissue, namely amnion mesenchymal cell, chorion mesenchymal cell and umbilical cord mesenchymal cell; and the origin of the other one is amniotic fluid cell. Besides, the invention also discloses an induction reprogramming method for producing cells capable of producing induced pluripotent stem (iPS) cells by efficient induction, including the following steps: cDNA containing pluripotent stem cell factor is respectively introduced into the four primary culture cells; the four primary cells in which cDNA is introduced are respectively cultured on appropriate culture mediums, primary iPS is obtained and then quality of iPS is optimized on appropriate culture mediums, and cloning of pluripotent stem cell can be primarily evaluated. In the invention, three mesenchymal cells of placenta origin and amniotic fluid cell all can be induced into iPS, wherein the chorion mesenchymal cell is compared with fibroblast, efficiency of induction reprogramming is improved by over 100 times, efficiency is about 2.3%, and the efficiency is slightly higher than that of horny cell; and a means which is more effective and more pertinent is provided for building disease model, screening drug and controlling oriented differentiation.

The present invention provides improved methods of prenatal diagnosis, monitoring, screening and/or testing. The invention is based, at least in part, on the discovery that amniotic fluid is a rich source of cell-free fetal RNA. Methods of isolation and analysis of fetal RNA are described, that can lead to information about fetal gene expression that is not available by other techniques. The inventive systems allow for a more comprehensive determination of a living human fetus' health, growth and development and for the prenatal diagnosis of a variety of diseases and conditions.

The invention discloses an amniotic fluid detection indicator composition, preparation thereof and a corresponding amniotic fluid detection pad. The amniotic fluid detection indicator composition is used by taking one or two of water, ethyl alcohol, acetone and N,N-dimethylformamide as a solvent or solvents, taking one or more than one of pulullan, sodium alginate, ethyl cellulose and sodium carboxymethylcellulose as a film-forming agent or film-forming agents, taking dioctyl phthalate as a plasticizer, taking ethylene glycol, glycerol and glycol ethylene ether as wetting agents, taking bromothymol blue sodium salt, bromoxylenol blue, sodium alizarine sulfonate and bromcresol purple as indicators, preparing an amniotic fluid detection indicator at the normal temperature, then coating a medical sanitary pad with the amniotic fluid detection indicator, and drying the medical sanitary pad to prepare an amniotic fluid detection pad. The amniotic fluid detection indicator composition is convenient to use, not easy to decolor and more easily acceptable to patients, and is capable of distinguishing amniotic fluid and urine; the whole process is simple to operate; the large-scale production is easy to implement.

The invention provides a kit for detecting genotype of human chromosome 21 STR (short tandem repeat). The kit comprises an amplification reagent and an amplification product detection reagent and mainly contains primers of 12 pairs of fluorescent markers, a molecular weight internal label containing the size of 14 fragments, an allele typing standard product and a quality control product. According to the kit disclosed by the invention, when the kit is used, the required quantity of specimens is small, the diagnosis is fast, and the kit is suitable for villi, amniotic fluid, blood and other tissues, and can be used for not only prenatal diagnosis, but also source analysis of extra chromosomes of a 21-trisomy aborted fetus; the kit can precisely diagnose the genotype and is conductive to presentation of diagnosis result and laboratory quality evaluation; and the kit can further realize fast, accurate, automatic and high-throughput detection of the number of chromosomes 21 and realize quality controllability and standardization of a detection result, and thus has clinical application prospects.

The invention discloses an amniotic fluid protein prediction method based on a recurrent neural network, and belongs to the technical field of big data and artificial intelligence. According to the method, a protein list verified by biological experiments in amniotic fluid of existing literatures and databases is used as a positive sample for model training; protein family information corresponding to the positive sample is deleted from a Pfam protein family information database, protein families with the number of proteins exceeding 5 in the families are searched for in the remaining proteinfamily information database, and five pieces of protein information are randomly selected from the protein families to serve as negative samples for model training. The method further comprises the steps of: dividing the positive sample data and the negative sample data into a training set, a verification set and a test set; and carrying out feature selection on protein features, building a model,training the model by using the training set, carrying out parameter adjustment on the verification set, and carrying out performance evaluation on the test set. The input is a protein feature and the output is a prediction result. The accuracy of amniotic fluid prediction is improved, and finally amniotic fluid protein prediction is achieved.

The invention provides an SNP locus for detecting an acute hemolytic transfusion reaction caused by a variant gene FUT1 of an H blood-group system, that is a new GA deletion mutation of 550th base and551th base from an initiation codon of an H-type variant gene encoding region. The invention provides new use of the variant gene FUT1 so as to provide an effective rapid gene diagnosis, gene screening and genetic counseling way for induced acute intravascular hemolytic transfusion reactions; proven by an application effect, the genic SNP locus and detection primers provided by the invention canbe used for effectively carrying out rapid detection on new H blood-group system variant gene mutant sites of peripheral blood and fetal villi or amniotic fluid of patients in clinical.

The present disclosure provides compositions composed of amniotic fluid and/or modified amniotic fluid, a pharmaceutically acceptable carrier, and optionally a placental tissue graft, micronized placental tissue components, or extracts derived therefrom. Also described are systems and apparatuses for administering or storing said compositions, as well as methods of treatment using said compositions.

The invention discloses an obstetric bed for assisting parturition in a delivery room in obstetrics and gynecology department. The obstetric bed comprises a base plate and a bed board movably arrangedabove the base plate, wherein a lifting pneumatic rod is arranged on a surface of the bed board, the top of the lifting pneumatic rod is connected with a backrest, a headrest is adhered on the surface of the backrest through a magic tape, first slide rails and second slide rails are arranged on the surface of the bed board, first inserting structures are embedded in the right end parts of the first slide rails, and the tops of the first inserting structures are connected with a mattress; second inserting structures are embedded in the left end parts of the first slide rails, and the tops of the second inserting structures are connected with a lochia collecting mechanism; third inserting structures are embedded in the second slide rails, the tops of lifting rods are connected with crus placing supports through ball heads, and pedals which are symmetrical relative to the transverse center line of the bed board are arranged on the surface of the bed board. The problems such as lochia collection are solved, the lochia such as amniotic fluid generated during delivery can be collected and then discharged through a collecting barrel.